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Abstract
Neisseria meningitidis and Bordetella pertussis are Gram-negative bacterial pathogens that can cause serious diseases in
humans. N. meningitidis outer membrane vesicle (OMV) vaccines and whole cell pertussis vaccines have been successfully
used in humans to control infections with these pathogens. The mechanisms behind their effectiveness are poorly defined.
Here we investigated the role of Toll-like receptor (TLR) 2 and TLR4 in the induction of immune responses in mice after
immunization with these vaccines. Innate and adaptive immune responses were compared between wild type mice and
mice deficient in TLR2, TLR4, or TRIF. TRIF-deficient and TLR4-deficient mice showed impaired immunity after immunization.
In contrast, immune responses were not lower in TLR22/2 mice but tended even to be higher after immunization.
Together our data demonstrate that TLR4 activation contributes to the immunogenicity of the N. meningitidis OMV vaccine
and the whole cell pertussis vaccine, but that TLR2 activation is not required.
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Introduction
The innate immune system senses microbes through a number
of receptors present on innate immune cells that can recognize a
wide variety of microbial structures [1]. This group of receptors is
often referred to as pattern recognition receptors (PRRs). There
are several classes of PRRs, including Toll-like receptors (TLRs),
C-type lectin like receptors, RIG-I like receptors, and Nod-like
receptors. The TLR family is the best characterized class to date.
In humans, 10 different TLRs have been described and each TLR
recognizes distinct microbial structures [2]. For example, lipo-
polysaccharide (LPS), a major component of Gram-negative
bacteria, activates TLR4, lipoproteins and several other structures
activate TLR2, unmethylated CpG DNA of bacteria and certain
viruses activate TLR9, and viral dsRNA is recognized by TLR3
[2]. Four adaptor proteins mediate TLR signalling: MyD88,
TRIF, MAL, and TRAM [3]. All TLRs signal through MyD88,
except TLR3, which signals solely through TRIF. Moreover,
TLR4 is the only TLR which utilizes both MyD88 and TRIF [4].
Activation of these proteins eventually leads to induction of pro-
inflammatory cytokines and type I interferon, respectively.
Activation of TLR7/8 and TLR9 also leads to the induction of
type I interferon, but in a MyD88-dependent manner [1].
The primary function of TLRs is to detect pathogens and
activate innate immune cells to clear the infection immediately.
However, TLRs also play an important role in the initiation of
adaptive immune responses [5,6]. Dendritic cells (DCs) are
thought to play a central role in linking innate and adaptive
immunity after TLR triggering, because of their superior capacity
to stimulate T cells [7]. Which TLR is activated determines what
types of cytokines and other factors are produced by the DCs,
which in turn dictates whether the CD4
+ T cells differentiate into
Th1, Th2, Th17, or Treg [1],[8]. Because TLR ligands can both
initiate and direct adaptive immunity, they have great potential as
adjuvants. However, the claim that TLR activation always plays
an important role in the induction of an adaptive immune
response after vaccination has been challenged recently [9].
Many of the currently licensed vaccines are live attenuated
strains or contain elements of killed microbes [5]. These vaccines
likely contain structures that are recognized by TLRs and
contribute to the immunogenicity. This has indeed been
demonstrated for a number of vaccines [5,10–13], but for the
majority of vaccines this information is still lacking. It is important
to identify the pathways induced by these successful vaccines for
the rational design of new vaccines and/or adjuvants. Moreover,
the human population is genetically very diverse and some
individuals might have deficiencies in the pathways that are
induced by the vaccine, which could explain why some individuals
respond poorly after vaccination [14]. We decided to study the
role of TLRs in the immunogenicity of two LPS-containing
vaccines against the Gram-negative bacterial pathogens Neisseria
meningitidis and Bordetella pertussis.
N. meningitidis is a leading cause of meningitis and sepsis
worldwide [15]. The bacterium can be divided into several
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W-135) capsular polysaccharide vaccines are available, but not for
serogroup B, because its capsular polysaccharide is not immuno-
genic. An attractive alternative for serogroup B is an outer
membrane vesicle (OMV) vaccine [16]. OMV vaccines have been
shown to be effective in controlling epidemics in Cuba, Norway,
and New Zealand, where one particular clone of N. meningitidis
serogroup B was causing high rates of meningococcal disease [16].
B. pertussis is the causative agent of whooping cough in humans. To
prevent this disease, whole cell pertussis vaccines have been used
for many decades in developed countries and are still used today in
developing countries. However, due to adverse effects the whole
cell vaccine has now been replaced in developed countries with a
safer subunit vaccine consisting of a few B. pertussis antigens
[17,18]. The N. meningitidis OMV vaccine and whole cell pertussis
vaccine both contain LPS and lipoproteins, which activate TLR4
and TLR2 respectively [19–23]. Ligands of these TLRs have been
shown to have adjuvant activity in numerous studies in mice
[11,24–27].
Here we investigated the role of TLR2 and TLR4 in the
induction of immune responses in mice after immunization with a
N. meningitidis OMV vaccine and a whole cell pertussis vaccine.
Innate cytokine induction, T cell responses, and antibody
production were compared between wild type mice and mice
deficientineitherTLR2,TLR4,orTRIF.Surprisingly,TLR22/2
mice were not compromised in any of the responses after
immunization. In contrast, TRIF-deficient and TLR4-deficient
mice showed impaired immunity after immunization. We conclude
that TLR4 activation contributes to the immunogenicity of the N.
meningitidis OMV vaccine and the whole cell pertussis vaccine, but
that TLR2 activation is not required.
Results
TRIF-deficient and TLR4-deficient mice have reduced
innate cytokines levels after immunization
As a N. meningitidis OMV vaccine we chose OMVs derived from
serosubtype P1.5-1,2-2. This serosubtype is one of the prevalent
variants in The Netherlands. Moreover, serosubtype P1.5-1,2-2 is
among the more immunogenic serosubtypes in humans and mice
[28–30]. As a whole cell pertussis vaccine we used a mixture of the
vaccine strains 134 and 509. In humans these vaccines are
administered with alum as the adjuvant [16–18]. However, we did
not include alum to study more specifically the intrinsic adjuvant
activity of the vaccines.
The role of TLR2 and TRIF in vaccine-induced responses after
immunization was examined by immunizing wild type C57BL/6
mice, TLR22/2 mice, and TRIF-deficient mice, which all have a
C57BL/6 background [31,32]. To investigate the role of TLR4,
responses were compared between TLR4-deficient C3H/HeJ
mice and wild type C3H/HeOuJ mice [33]. All mouse strains
were immunized subcutaneously with either PBS, N. meningitidis
OMVs, or whole cell pertussis vaccine. After two and four hours a
blood sample was taken from all mice to analyze serum cytokine
levels of IL-1b, IL-6, IL-10, IL-12p70, RANTES, and TNF-a.I n
wild-type mice N. meningitidis OMVs induced modest levels of IL-6
and RANTES measurable at 2 and 4 h compared to PBS (Fig. 1A
and data not shown). OMV-induced IL-6 levels at 2 hours were
significantly lower in TRIF-deficient and TLR4-deficient mice
and tended to be higher in TLR22/2 mice. Levels of OMV-
induced RANTES were not impaired in the deficient mouse
strains. Whole cell pertussis vaccine induced measurable levels of
IL-6, IL-12p70, RANTES, and IL-10 (Fig. 1B and data not
shown). Again TRIF deficient mice and TLR4-deficient mice were
clearly compromised in cytokine induction compared to wild type
mice. TLR22/2 mice were not impaired in cytokine production,
IL-6 even tended to be higher. These results suggest that early
serum cytokine production in vivo after immunization with N.
meningitidis OMVs or whole cell pertussis vaccine requires mainly
LPS signalling and not TLR2 activation.
Comparison of antigen-specific antibody levels
The amount of antibodies was determined in all sera. It has
been demonstrated previously that class switching to IgG2a/c
and IgG2b depends on a Th1 response and class switching to
IgG1 and IgE depends on a Th2 response [34–36]. Therefore, to
analyze antibody production and the type of immune response
that was induced, antigen-specific total IgG, antigen-specific IgG
subclasses, and total IgE were determined in the serum. N.
meningitidis OMVs induced a Th1-dependent antibody profile in
wild type C57BL/6 mice, reflected by high levels of IgG2b and
IgG2c, almost no IgG1, and no increase in total IgE compared
to PBS injected mice (Fig. 2A). IgG3 levels were also very
low. Strikingly, TLR22/2 mice immunized with N. meningitidis
OMVs were not impaired at all in the antibody response, IgG1
and IgG3 levels even tended to be higher. On the other hand,
N. meningitidis OMVs induced significant lower amounts of IgG in
TRIF-deficient mice, which was mainly due to lower levels of
IgG2b and IgG2c (Fig. 2A). In contrast, IgG1 and IgG3 levels to
OMVs were significantly higher in TRIF-deficient mice com-
pared to wild type mice. TLR4-deficiency did not significantly
reduce antibody levels to OMVs, although for IgG, IgG2a,
IgG2b, and IgG3 there was a tendency for reduced levels in
TLR4-deficient mice (Fig. 2B).
Bactericidal antibodies are currently considered to be the most
important correlate of protection for meningococcal disease [37],
[38]. Furthermore, IgG2a/c, IgG2b, and IgG3, but not IgG1,
isotypes can activate complement [39]. We tested the bactericidal
activity of the sera of all mice immunized with N. meningitidis
OMVs. Consistent with the lower IgG2b and IgG2c levels, TRIF-
deficient mice had significantly lower levels of bactericidal
antibodies compared to wild type mice (Fig. 2C). Similar
amounts of bactericidal antibodies were induced in wild-type
and TLR22/2 mice. Finally, TLR4 deficient mice tended to
have less bactericidal antibodies than wild-type mice (Fig. 2D).
Together these results suggest that LPS signalling also contributes
to the generation of bactericidal antibodies after immunization
with N. meningitidis OMVs, whereas TLR2 activation is not
required.
The differences between the different mouse strains in antibody
levels were quite similar for the mice that received whole cell
pertussis vaccine and the mice that received N. meningitidis OMVs.
Again TLR22/2 mice did not show any defects in the induction
of antibodies (Fig. 3A). Moreover, IgG3 and IgE levels tended to
be higher in TLR22/2 mice compared to wild type mice. TRIF-
deficient mice had significant lower amounts of IgG, which was
mainly due to lower levels of isotypes IgG2b and IgG2c, as with N.
meningitidis OMVs. However, in contrast to N. meningitidis OMVs,
whole cell pertussis vaccine did not induce higher levels of IgG1
and IgG3 in TRIF-deficient mice. TLR4 deficient mice had lower
amounts of all antibody isotypes compared to wild-type mice,
except IgE (Fig. 4B). The differences were significant for IgG,
IgG2a and IgG1. The whole cell pertussis vaccine also induced the
production of total IgE, in contrast to N. meningitidis OMVs. In
summary, our results demonstrate that LPS signalling contributes
to the antibody response after immunization with N. meningitidis
OMVs and whole cell pertussis vaccine. However, activation of
TLR2 does not seem to contribute to the antibody response.
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equally after in vitro antigen restimulation
Also the spleen was taken from the mice immunized as
described above. Spleen cells were restimulated with antigen or
peptides for 4 days and proliferation of the cells was assessed by
measuring [
3H]thymidine incorporation. Spleen cells of mice with
a C57BL/6 background and immunized with either N. meningitidis
OMVs or PBS were restimulated with two PorA peptides, which
were previously identified as two P1.5-1,2-2 PorA epitopes
recognized by C57BL/6 mice (M. Poelen and C. van Els,
unpublished data). Spleen cells from N. meningitidis OMV
immunized mice clearly proliferated in response to the two
peptides, suggesting that CD4
+ T cells specific for those epitopes
were generated after immunization (Fig. 4A). Interestingly, there
was no difference between the three mouse strains in spleen cell
proliferation. Which epitopes of P1.5-1,2-2 PorA were recognized
by C3H/HeJ and C3H/HeOuJ mice was not known to us.
Therefore, spleen cells of these mice immunized with either PBS
or N. meningitidis OMVs were restimulated with different peptides
pools spanning the entire P1.5-1,2-2 PorA protein sequence (data
not shown). We found that one peptide pool induced the highest
proliferation of spleen cells derived from N. meningitidis OMV
immunized mice (Fig. 4B). There was also no difference in spleen
cell proliferation between TLR4-deficient and wild-type mice.
Together these results suggest that activation of TLR2 or TLR4
has no influence on CD4
+ T cell proliferation after immunization
with N. meningitidis OMVs.
To investigate CD4
+ T cell proliferation after whole cell
pertussis vaccine immunization, spleen cells of all the different
mice immunized with whole cell pertussis vaccine or PBS were
restimulated with a purified B. pertussis antigen, filamentous
hemagglutinin (FHA, Fig. 4C). Clearly, only spleen cells of mice
that received whole cell pertussis vaccine proliferated. Moreover,
as with the PorA peptides, there were no significant differences
between the mouse strains. Thus it seems that also for whole cell
pertussis vaccine, TLR2 or TLR4 activation has little influence on
CD4
+ T cell proliferation.
LPS signalling and TLR2 activation influence quality of T
cell responses
Naı ¨ve CD4
+ T cells can differentiate into Th1, Th2, Th17, or
Treg cells. Th1 cells produce IFN-c, Th2 cells produce IL-4, IL-5,
and IL-13, Th17 cell produce IL-17, and most Treg cell subsets
produce IL-10 [40,41]. These cytokines were measured in the
supernatant of the spleen cells stimulated with antigen or peptides
to identify the type of T cell responses that were induced. Spleen
cells of mice with a C57BL/6 background immunized with either
N. meningitidis OMVs or PBS were restimulated with two P1.5-1,2-
Figure 1. Serum cytokine levels shortly after vaccination. Two and four hours after immunization blood samples were taken from all mice and
cytokine levels in the sera were analyzed with Luminex. Results for N. meningitidis OMVs are shown in panel A, results for whole cell pertussis vaccine
are shown in panel B. There were 3 mice per group for the animals that received PBS and 6 mice per group for N. meningitidis OMVs and whole cell
pertussis vaccine. The data are expressed as means, error bars represent S.E.M. An asterisk indicates a significant difference compared to the wild type
group, * indicates p,0.05, ** indicates p,0.01, *** indicates p,0.001.
doi:10.1371/journal.pone.0015692.g001
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both peptides. Cells from TLR22/2 mice immunized with N.
meningitidis OMVs tended to produce more IL-5, IL-10, IL-13, and
IFN-c after stimulation with peptide 11–24/25 (Fig. 5A). The
other peptide, 4–52/53, generally induced higher production of
cytokines by spleen cells of all the mice immunized with N.
meningitidis OMVs (Fig. 5B). Moreover, peptide 4–52/53 induced
spleen cells of TRIF-deficient mice to produce significant higher
levels of IL-4, IL-5, and IL-13 and tended to produce less IFN-c
compared to spleen cells of wild type C57BL/6 mice. Clearly, the
response was skewed towards a Th2 response in the TRIF-
deficient mice, consistent with what we noticed at the antibody
level (Fig. 2A). Spleen cells of TLR22/2 mice also produced
significant higher levels of IL-13 than wild type spleen cells
(Fig. 5B). Furthermore, IL-5 and IL-17 tended to be higher.
Spleen cells of TLR4-defcient and wild-type mice were restimu-
lated with different peptide pools. Since peptide pool 6 induced the
highest proliferation, cytokine production by cells stimulated with
this pool was measured (Fig. 5C). Remarkably, spleen cells from
TLR4-deficient mice immunized with N. meningitidis OMVs did
not produce any of the cytokines analyzed, although the cells
clearly proliferated as much as the cells from wild-type mice
(Fig. 4B). In contrast, wild-type cells produced all cytokines, except
IL-4. Overall these results show that after immunization of wild
type mice with N. meningitidis OMVs, antigen-specific T cells
mainly produce IFN-c. This suggests that N. meningitidis OMVs
mainly induce a Th1 response in wild type mice. We also
demonstrate that some antigen-specific T cells produce IL-17.
Furthermore, our results suggest that TLR4 activation is required
for the generation of cytokine producing T cells and that TRIF
signalling contributes to a Th1 response. Finally, TLR2 activation
is not required for the generation of cytokine producing T cells,
but in contrast seems somewhat inhibitory.
Spleen cells of the different mouse strains immunized with whole
cell pertussis vaccine were restimulated with purified FHA antigen.
The strong proliferation of cells of mice with a C57BL/6
background after antigen restimulation was associated with the
presence of IL-2 and IL-17 (Fig. 6A). In addition, low amounts of
IFN-c and IL-5 were only produced by the spleen cells of TRIF-
deficient mice immunized with whole cell pertussis vaccine. FHA
stimulated spleen cells of wild-type C3H/HeOuJ mice immunized
with whole cell pertussis vaccine produced all cytokines measured
(Fig. 6B). Levels of IL-17 were especially high followed by IFN-c.I n
contrast, reminiscent of the N. meningitidis OMVs model, FHA
stimulated spleen cells of TLR4-deficient C3H/HeJ mice hardly
produced any cytokines, even though they proliferated as much as
wild-type C3H/HeOuJ spleen cells. Together, our results demon-
strate that whole cell pertussis vaccine immunization induced a
Th17/Th1 response, which was impaired in TLR4-deficient mice.
Discussion
In the present study, we demonstrate that TLR4 signalling by
LPS contributes to generation of adaptive immune responses after
immunization with N. meningitidis OMVs or whole cell pertussis
vaccine, while TLR2 activation was not required. Instead,
TLR22/2 mice overall showed higher rather than lower
responses compared to C57BL/6 mice after immunization with
the N. meningitidis and B. pertussis vaccines. For example, IL-6 serum
levels just after vaccination tended to be higher in the
TLR22/2 mice. At the antibody level, IgG1 and IgG3 tended
to be higher in N. meningitidis OMVs immunized TLR22/2 mice,
whereas IgG3 and IgE tended to be higher in TLR22/2 mice
immunized with whole cell pertussis vaccine. Finally, spleen cells
of TLR22/2 mice immunized with N. meningitidis OMVs
restimulated with P1.5-1,2-2 PorA peptides produced higher levels
of several cytokines, including significantly higher levels of IL-13.
Together these results indicate that TLR2 activation inhibited
immune responses, especially Th2 responses, after vaccination.
Similarly, TLR2-deficient mice were shown to have greatly
enhanced Th1 and Tc1 responses after vaccination with yellow
fever vaccine YF-17D [13]. Moreover, it has been demonstrated
recently that activation of TLR2 by the yeast cell wall derivative
zymosan induces a Treg response [42,43]. On the other hand,
TLR2 ligands have been shown to have adjuvant activity in
several studies [10,11,27,44]. In addition to induction of a Treg
response, TLR2 activation has also been shown to induce a Th1
reponse [45], or Th2 response [46–48]. How TLR2 activation can
lead to all these different responses is currently not clear, but it
might depend for example on which ligand is used, whether the
ligand is recognized by TLR2/TLR1 or TLR2/TLR6, or which
cell type is targeted. In any case, our results show that TLR2
activation is not required for induction of adaptive immunity when
TLR4 is also activated. However, even TLR4-deficient mice still
develop adaptive immune responses after vaccination. This
residual response might be due to TLR2 activation. To address
this issue, also mice deficient in both receptors should be tested.
Moreover, the vaccines might contain ligands of other TLRs or
PRRs, which also contribute to the immunogenicity.
TRIF-deficient mice clearly showed altered immune responses
after immunization with N. meningitidis OMVs and whole cell
pertussis vaccine. Antigen- specific IgG2b and IgG2c levels were
significantly reduced for both vaccines, which resulted in less
bactericidal antibodies in the case of N. meningitidis OMVs. In
addition, spleen cells of TRIF-deficient mice immunized with N.
meningitidis OMVs restimulated with PorA peptides produced
significantly higher amounts of IL-4, IL-5, and IL-13, while IFN-c
production was reduced. Together these data show that activation
of the TRIF pathway leads to a Th1 response after immunization
with N. meningitidis OMVs or whole cell pertussis vaccine.
Therefore, targeting of the TRIF pathway is important, because
for both vaccines optimal responses after vaccination should
include Th1-responses. Induction of the TRIF pathway eventually
leads to the induction of type I interferon, which is not induced by
the MyD88 pathway downstream of TLR2 or TLR4 [3,32,49].
We have shown previously that ligands of TLR3, TLR4, TLR7,
and TLR9 enhance the immunogenicity of a N. meningitidis outer
membrane vaccine by promoting Th1-dependent antibody
production, whereas ligands of other TLRs did not show adjuvant
activity [25]. Importantly, activation of TLR3, TLR4, TLR7, and
TLR9 leads to the induction of type I interferon, but activation of
the other TLRs does not [50]. Possibly, TLR-induced type I
Figure 2. Antibody titers of mice after immunization with N. meningitidis P1.5-1,2-2 OMVs. Mice were immunized with N. meningitidis
P1.5-1,2-2 OMVs and antigen-specific titers of IgG, IgG1, IgG2a/c, IgG2b, and IgG3 in sera were determined with ELISA. Also total IgE in sera of mice
immunized with PBS or N. meningitidis P1.5-1,2-2 OMVs was measured with ELISA. Results for C57BL/6, TLR22/2, and TRIF-deficient (TRIFdef) mice
are shown in panel A, results for C3H/HeOuJ and C3H/HeJ mice are shown in panel B. Levels of serum bactericidal antibodies after immunization with
N. meningitidis P1.5-1,2-2 OMVs are shown in panel C. Data are expressed as means of log10 titers for 6 mice per group, except levels of serum
bactericidal antibodies in C57BL/6 and TLR22/2 mice (n=12). Error bars represent S.E.M. An asterisk indicates a significant difference compared to
the wild type group, * indicates p,0.05, ** indicates p,0.01.
doi:10.1371/journal.pone.0015692.g002
Differential Effect of TLR2 and TLR4 in Immunity
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e15692Differential Effect of TLR2 and TLR4 in Immunity
PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e15692interferon drives Th1 development and contributes to the adjuvant
effect of TLR ligands. Indeed, the adjuvant effect of poly IC by
inducing CD4
+ Th1 immunity and humoral immunity depends on
type I interferon [51,52]. Interestingly, the vaccine adjuvant
Monophosphoryl lipid A, a low-toxicity LPS derivative, has been
shown to preferentially activate the TRIF pathway [53].
We also show that TLR4-deficient mice have impaired immune
responses after immunization with N. meningitidis OMVs and whole
cell pertussis vaccine. After whole cell pertussis immunization of
the TLR4-deficient C3H/HeJ mice, IL-6 and IL-12p70 were
almost undetectable in the serum. Moreover, IgG, IgG1, and
IgG2a levels were significantly lower in these mice. In contrast,
others have found that antibody levels are not decreased in TLR4-
deficient mice after immunization with whole cell pertussis vaccine
[54,55]. However, in these studies alum was added to the vaccine
as an adjuvant, which mainly enhances humoral immunity.
Presumably, the adjuvant effect of LPS is more redundant in the
presence of another potent adjuvant like alum.
Surprisingly, TLR4-deficient C3H/HeJ mice did not have
significantly decreased OMV-directed antibody titers compared to
wild-type C3H/HeOuJ mice. By contrast, we previously found
that LPS-deficient N. meningitidis outer membrane complexes
(OMCs) induced more than 1000-fold lower antibody titers in
TLR4-proficient mice than wild type OMCs [25]. This suggests
that LPS improves the immune response not only by activating
TLR4, but also by other mechanisms. Possibly, LPS could target
the vaccine to antigen presenting cells by binding to other
receptors, for example CD14 or C-type lectins.
In contrast to antibody levels, cytokine production after
restimulation with PorA peptides was severely impaired in spleen
cells from TLR4-deficient C3H/HeJ mice. Similarly, it has been
demonstrated that whole cell pertussis vaccine immunization led
to comparable antibody titers in TLR4-deficient and wild type
mice, but IFN-c and IL-17 production of T cells after antigen
restimulation was much lower for TLR4-deficient mice [55].
These results suggest that TLR4 activation is more important for
the induction of effector T cells than for antibody production.
Remarkably, the TLR4-deficient spleen cells restimulated with
PorA peptides or FHA proliferated equally well as spleen cells
from the wild-type mice. This suggests that in TLR4-deficient
Figure 3. Antibody titers of mice after immunization with whole cell pertussis vaccine. Mice were immunized with whole cell pertussis
vaccine (Bordetella pertussis) and antigen-specific titers of IgG, IgG1, IgG2a/c, IgG2b, and IgG3 in sera were determined with ELISA. Also total IgE in
sera of mice immunized with PBS or whole cell pertussis vaccine was measured with ELISA. Results for C57BL/6, TLR22/2, and TRIF-deficient
(TRIFdef) mice are shown in panel A, results for C3H/HeOuJ and C3H/HeJ mice are shown in panel B. Data are expressed as means of log10 titers for 6
mice per group. An asterisk indicates a significant difference compared to the wild type group, * indicates p,0.05, ** indicates p,0.01.
doi:10.1371/journal.pone.0015692.g003
Figure 4. Proliferation of spleen cells after restimulation with antigen or peptide. Spleens were taken from the mice after immunizations
and spleen cells were incubated for 4 days with medium, antigen, or peptides, after which [
3H]thymidine incorporation was determined. Spleen cells
of C57BL/6, TLR22/2, and TRIF-deficient (TRIFdef) mice immunized with PBS (3 mice per group) or N. meningitidis P1.5-1,2-2 OMVs (6 mice per group)
were restimulated with 1 mM of peptides 11–24/25 and 4–52/53 (A). Spleen cells of C3H/HeOuJ and C3H/HeJ mice immunized with PBS (3 mice per
group) or N. meningitidis P1.5-1,2-2 OMVs (6 mice per group) were restimulated with peptide pool 6 (1 mM of each peptide, B). Spleen cells of C57BL/
6, TLR22/2, TRIF-deficient, C3H/HeOuJ, and C3H/HeJ mice immunized with PBS (3 mice per group) or whole cell pertussis vaccine (B. pertussis, 6 mice
per group) were restimulated with 500 ng/ml of FHA antigen (C). Data are expressed as means of stimulation indices.
doi:10.1371/journal.pone.0015692.g004
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+ T cells were generated without
effector function. Interestingly, it has been shown that DCs that
had a mature phenotype but did not produce IL-12 and other
pro-inflammatory cytokines, promoted expansion of CD4+ T
cell populations lacking effector function [56]. Possibly, this type
of DCs was induced in the TLR4-deficient mice. After whole cell
pertussis vaccine immunization, serum levels of IL-6 and IL-
12p70 were very low in C3H/HeJ mice. In addition, it has been
demonstrated that serum IL-12p70 production in vivo after
administration of a TLR9 ligand depended entirely on DCs [57].
Unfortunately, in our experiments N. meningitidis OMVs were not
potent enough to enhance serum IL-12p70 levels even in wild-
type animals, but in a recent report where a 10-fold higher dose
of a comparable preparation of native N. meningitidis OMVs was
used, IL-12p70 was elevated in serum of wild-type mice but not
in TLR4-deficient mice. Serum levels of MCP-1, TNF-a,I L - 6 ,
and IL-10 were also much lower in the TLR4-deficient mice
[58].
In conclusion, our results show that two successful LPS-
containing vaccines against the Gram-negative bacterial pathogens
N. meningitidis and B. pertussis require TLR4 signaling for optimal
immunogenicity and induction of Th1 responses in mice. On the
other hand, TLR2 activation was not required. These findings
confirm that TLR4 and the TRIF pathway are attractive targets
for adjuvants in vaccines.
Materials and Methods
Ethics statement
Animal experiments were approved by the Netherlands Vaccine
Institute’s Committee on Animal Experiments (DEC), project
review nrs. 200800223 and 200800224.
Figure 5. Cytokines produced by spleen cells after restimulation with P1.5-1,2-2 PorA peptides. Spleen cells from C57BL/6, TLR22/2,o r
TRIF-deficient (TRIFdef) mice immunized with PBS or N. meningitidis P1.5-1,2-2 OMVs were incubated for 4 days with peptide 11–24/25 (A) or peptide
4–52/53 (B). Spleen cells from C3H/HeOuJ and C3H/HeJ mice immunized with PBS or N. meningitidis P1.5-1,2-2 OMVs were incubated for 4 days with
peptide pool 6 (C). Cytokines IL-4, IL-5, IL-10, IL-13, IL-17, and IFN-c were determined in the supernatant with Luminex. Data are expressed as means
of three mice per group (PBS), or six mice per group (N. meningitidis OMVs), error bars represent S.E.M. An asterisk indicates a significant difference
compared to the wild type group, * indicates p,0.05, ** indicates p,0.01.
doi:10.1371/journal.pone.0015692.g005
Figure 6. Cytokines produced by spleen cells after restimulation with FHA. Spleen cells from C57BL/6, TLR22/2, TRIF-deficient (TRIFdef)
mice (A), or C3H/HeOuJ and C3H/HeJ mice (B) immunized with PBS or whole cell pertussis vaccine were incubated for 4 days with 500 ng/ml FHA
Cytokines IL-2, IL-4, IL-5, IL-10, IL-13, IL-17, and IFN-c were determined in the supernatant with Luminex. Data are expressed as means of three mice
per group (PBS), or six mice per group (whole cell pertussis vaccine), error bars represent S.E.M. An asterisk indicates a significant difference compared
to the wild type group, * indicates p,0.05, ** indicates p,0.01.
doi:10.1371/journal.pone.0015692.g006
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Specific-pathogen-free C57BL/6J, C3H/HeOuJ (TLR4-profi-
cient) and C3H/HeJ (TLR4-deficient) mice were purchased from
Charles River Laboratories. TLR22/2 mice [31] and TRIF-
deficient mice [32], both from a C57BL/6 background, were
kindly provided respectively by Dr. Shizuo Akira (Osaka
University, Japan) and Dr. Bruce Beutler (Scripps Research
Institute, La Jolla, CA) via Dr. Tom van der Poll (Academic
Medical Center, Amsterdam, the Netherlands). For experiments,
female mice were used, aged 10–14 weeks.
Vaccine preparation
The OMV vaccine was obtained from the PorB/RmpM-
negative N. meningitidis strain TR52 [P1.5-1,2-2] [59] by
extraction of bacteria with 0.5% deoxycholate in 0.1 M Tris-
HCl-10 mM EDTA (pH 8.6) and were purified by differential
centrifugation [60]. OMVs were stored at 4uC and diluted prior
to immunization to 20 mg/ml in PBS. For preparation of the
whole cell pertussis vaccine, B. pertussis strains 134 and 509 were
grown in defined synthetic medium [61]. After 18–22 hours of
culture, bacteria were heat inactivated for 10 min at 56uCi nt h e
presence of 16 mM formaldehyde. Next cells were centrifuged
for 10 min at 16,1006g and resuspended in PBS to 200
international opacity units (IOU)/ml. The suspensions were
stored at 4uC. Prior to immunization, both strains were
mixed 1:1 and diluted to a final concentration of 16 IOU/ml
in PBS.
Immunizations
Mice were immunized subcutaneously on days 0 and 21 with
250 ml PBS or 5 mgo fN. meningitidis P1.5-1,2-2 OMVs in 250 ml
PBS. Whole cell pertussis vaccine (4 IOU in 250 ml PBS) was
administered subcutaneously on days 0 and 28. Groups that
received PBS contained 3 mice per group and groups that received
OMVs or whole cell pertussis vaccine contained 6 animals per
group. A blood sample of all mice was taken 2 and 4 hours after
immunization. From the mice that received PBS or N. meningitidis
P1.5-1,2-2 OMVs blood and spleen were taken on day 28. From
the mice that received whole cell pertussis vaccine blood and
spleen were taken on day 42. Sera were collected and stored at
220uC. Single-cell suspensions of spleen cells were produced by
mechanical dissociation of organs through 70-mm-pore-size nylon
filters. Spleen cells were used either freshly or after freezing and
storage at 2135uC.
Antigen-specific antibodies
Antigen-specific IgG, IgG1, IgG2a/c, IgG2b, and IgG3
antibodies were determined by enzyme-linked immunosorbent
assay (ELISA) as described previously [25] with slight modifica-
tions. Briefly, flat-bottom 96-well microtiter plates (Immulon 2;
Nunc) were coated overnight at room temperature with 100 ml/
well 5 mg/ml N. meningitidis P1.5-1,2-2 OMVs (4 mg/ml PorA) in
PBS, or 2 IOU/ml of B. pertussis strain 509 (inactivated as
described above) in PBS. Plates were incubated with serial
dilutions of the sera of the immunized mice (100 ml/well) at
37uC for 1 h. Antibody isotypes were detected with anti-mouse
antibodies conjugated to horseradish peroxidase (Southern
Biotechnology Associates, Inc.). Next, peroxidase substrate was
added to the wells and the reaction was stopped by the addition of
2MH 2SO4. A four-parameter curve fit was made for optical
density values of the serial dilutions, and the antibody titer was
calculated in reciprocal dilutions that gave 50% of the maximum
absorbance. The results are expressed as log10 titers.
Total IgE
Total IgE levels in the sera were measured by ELISA as
described previously [25]. Briefly, flat-bottom 96-well microtiter
plates were coated with rat anti-mouse IgE monoclonal antibody
(BD Biosciences) and incubated overnight at 4uC. Next, the plates
were incubated for 1 h at room temperature with the sera of the
immunized mice and purified mouse IgE clone C48-2 (BD
Biosciences) as a standard. For detection of IgE, biotinylated anti-
mouse IgE (BD Biosciences) was used followed by streptavidin-
HRP (Sanquin). Peroxidase substrate was used as a substrate, and
the reaction was stopped with 2 M H2SO4. The absorbance was
determined at 450 nm.
Serum bactericidal assay
The sera of immunized mice were diluted 1:5 in Gey’s balanced
salt solution plus 0.5% bovine serum albumin and then heat
inactivated for 30 min at 56uC. Next, twofold serial dilutions of the
sera, together with N. meningitidis P1.5-1,2-2 (10
4 CFU/ml), were
incubated in 96-well plates at room temperature for 15 min. After
the addition of baby rabbit complement (20% of total volume)
plates were incubated at 37uC for 1 h. Bacteria were plated on GC
medium base (Difco Laboratories) supplemented with IsoVitaleX
(Becton Dickinson) and grown overnight at 37uCi n5 %C O 2 in a
humid atmosphere. The serum bactericidal titer was determined
as the reciprocal serum dilution that gave more than 90% killing of
the number of bacteria used. The results are expressed as log10
titers.
Peptide synthesis
Overlapping 18-mer peptides covering the entire B. pertussis
P.69 Prn protein or N. meningitidis P1.5-1,2-2 PorA protein were
prepared by solid-phase synthesis using N
a-(9-fluorenyl)methox-
ycarbonyl (FMOC)-protected amino acids and a Syro II
simultaneous multiple-peptide synthesizer (MultiSyntech GmbH,
Witten, Germany). The purity and identity of the synthesized
peptides were assessed by reverse-phase high-performance liquid
chromatography and mass spectometry.
Spleen cell proliferation
Spleen cells from immunized mice were cultured at 1.5610
5 in
150 ml IMDM (Gibco BRL) supplemented with 100 units/ml
penicillin, 100 mg/ml streptomycin, 300 mg/ml L-glutamine
(Gibco BRL), 10% heat-inactivated fetal calf serum (FCS) (Gibco
BRL), and 50 mM beta-mercaptoethanol in 96-well round-bottom
plates (Greiner). Spleen cells were co-cultured with either medium,
1 mM of P1.5-1,2-2 PorA peptides, or 500 ng/ml purified FHA
(Kaketsuken). On day 4, 100 ml of supernatant was removed and
stored at 220uC. Next, 0.5 mCi (18.5 kBq) [
3H]thymidine
(Amersham) was added to the wells, and cells were cultured for
another 18 h. Cells were harvested, and [
3H]thymidine incorpo-
ration was determined as counts per minute using a Wallac 1205
Betaplate liquid scintillation counter. Results are expressed as
stimulation indices from triplicate wells, calculated as (counts per
minute of cultures in the presence of antigen)/(counts per minute
of cultures in the presence of medium only).
Luminex
A 6-plex Bio-Plex assay (Bio-Rad) containing beads for mouse
IL-1b, IL-6, IL-10, IL-12p70, RANTES, and TNF-a was used to
measure levels of these cytokines in the sera of the mice taken 2
and 4 hours after immunization. A 7-plex Bio-Plex assay (Bio-
Rad) containing beads for mouse IL-2, IL-4, IL-5, IL-10, IL-13,
IL-17, and IFN-c was used to determine amounts of these
Differential Effect of TLR2 and TLR4 in Immunity
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antigen or peptide. Cytokine concentrations were determined with
a Bio-Plex system (Bio-Rad).
Statistics
One-way analysis of variance (ANOVA) was performed,
followed by the post-hoc Dunnett t test, to analyze differences in
means between the experimental groups of C57BL/6 mice,
TLR22/2, and TRIF-deficient mice (GraphPad Prism 4). The
unpaired two-tailed Students’ t test was used to analyze differences
in means between the experimental groups of C3H/HeOuJ and
C3H/HeJ mice. Variances were compared with the F-test. In case
of significantly different variances (p,0.05), the Welch’s correction
was included (GraphPad Prism 4). In case the SD of one of the
means was 0, the One-sample T test was used instead (SPSS
Statistics 17.0). P values of ,0.05 were considered significant.
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